Stockchase Opinions

Charles Taersk Reliq Health Techniques RHT-X DON'T BUY Oct 17, 2018

Unfortunately their technology has been slowing getting out into the market and now they have a receivables collection financial issue. It does not look good, he says.

$0.370

Stock price when the opinion was issued

computer parts mnfctr
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

TOP PICK
Remote monitoring of chronic disease. Real-time reporting to doctors. Slowed by Covid. Cashflow positive this quarter. Subscription model. Solid growth trajectory. CEO has a lot of skin in the game. No dividend.
TOP PICK
Remote monitoring business. When people leave the hospital, they have the technology to help monitor them. Gives the ability to track and keep healthcare costs down. Continues to add more doctor groups and healthcare regions that are recurring revenue streams. $24M run rate for this year. Margin is 45%. Valuation is attractive.
BUY
Real-time, remote medical reporting from patient to care providers. Fits and starts over the years. Should be rolling up to cashflow positive. Nice runway with great growth rate. Adding new partners. Monthly subscription. Could have a bright future in next couple of years.
PAST TOP PICK
(A Top Pick Sep 02/21, Down 61%) It is in the home monitoring business which could be huge one day. The business is operating well and signing up more patients. It receives around $50.00 per patient per month. It is a good time to buy now. A small cap.
COMMENT
He shorted it because of poor valuation. You should read the short report that came out a couple of months ago.
PAST TOP PICK
(A Top Pick Sep 02/21, Down 56%) More electronic home care will eventually bring down health care costs. It is signing more doctors' groups, etc. but still needs time to get patients hooked up. It should have 200 000 patients in the system next year with each one paying $40 U.S. per month. A high margin business. Looking for it to deliver
PAST TOP PICK
(A Top Pick Oct 15/21, Down 54%) Their software connects to hardware so that people can monitored health ailments at home. FHT has been adding patient groups. The business offers recurring revenues whereby they're paid each month in US dollars. They project they will be EBITDA-positive this year. He got stopped-out of this, but wants to get back in. He sees potential. The CEO owns a lot of shares.
TOP PICK
It provides software for hardware for patients in their homes. Has 8 1/2 million in revenue up from 1 1/2 million the year before. It expects to have 100 000 patients at $50 per month per patient with maybe a 50% margin by the end of this year. It had a couple of false starts and is now at an inflection point. It was a top pick in the past and he has just bought back in. The company may do a buy back and is a possible takeover target.
COMMENT
Underlying business has been operating fantastically. Comes down to size and market cap. Still ramping up.
DON'T BUY

Healthcare tech company.
Have recently been short the stock in the past.
Not sure how financials are going to improve.
Poor management of company.
Not a good long term holding.